🛡️ RVMD $3.1M Premium Collection — Bullish Desk Bets the Post-ASCO Floor Holds

📅 June 25, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just collected $3.1 MILLION in premium by selling 3,000 puts on Revolution Medicines this morning — a bold, bullish/neutral bet that RVMD's post-ASCO floor holds into August. This is not a panic buy or a fearful hedge: this is a sophisticated desk monetizing rich biotech catalyst IV after one of the most striking Phase 3 wins in recent oncology history. Translation: smart money is getting paid to commit to buying RVMD at $170 — about 6% below today's price — because they think the stock isn't going there.

---

📊 Company Overview

Revolution Medicines (RVMD) is a clinical-stage oncology company built around a single transformative insight: block RAS proteins while they are active (the "ON" state), not just when they carry one specific mutation.

• Market Cap: ≈$37.6B (clinical-stage, pre-revenue)
• Industry: Biotechnology / Clinical-Stage Oncology
• Primary Business: RAS(ON) inhibitor pipeline targeting KRAS/NRAS/HRAS mutations in pancreatic cancer, lung cancer, and beyond
• Lead Asset: daraxonrasib (RMC-6236) — a multi-selective RAS(ON) inhibitor with a freshly-minted Phase 3 win in 2nd-line metastatic pancreatic cancer (presented at ASCO Plenary, May 31, 2026)
• Stock: Near 52-week highs of $184.39 following a ≈5x run off the lows; the post-ASCO re-rating has been dramatic

---

💰 The Option Flow Breakdown

📊 What Just Happened

A single, size-proven fresh SHORT PUT position opened on the tape at 11:13:33 ET this morning. Here is every detail from the tape:

Flow tag: ⚡ LIT — this was a genuine displayed-market sale executed at or near the bid on the lit options tape. The tape shows no paired stock block; this is a pure options-only position.

---

✅ OI Check — RESOLVED: Fresh Short-Put OPEN Confirmed

The June 26 pre-market OPRA snapshot (reflecting June 25 end-of-day) is in, and it confirms the size-proven read: this was a fresh opening SELL (STO) of the August 21 $170 put.

Open interest rose from zero to 3,001 — Δ +3,001, ≈ the full 3,000-contract print. This is an unambiguous fresh open of a short put (premium-collection / bullish-to-neutral), not a close. The interpretation below stands.

---

🤓 What This Actually Means — Plain English

Let's decode this one step at a time, because it is not your typical "big buy" headline.

What is a short put? When someone sells a put option, they collect the premium upfront — $10.30 per share, or $3.1M total here — and in exchange they take on an obligation to buy RVMD stock at $170 if it falls below that level by August 21, 2026. Think of it like being a landlord who gets paid rent every month in exchange for agreeing to buy the house from the tenant at a set price if the market falls.

Is this bullish or bearish? It is bullish/neutral. The seller profits if RVMD stays above $170. They lose money only if RVMD falls below $159.70 (the $170 strike minus the $10.30 credit collected — that is the effective cost basis if assigned). The seller is explicitly saying: "I am comfortable owning RVMD at ≈$160, and I think it stays above $170 through August." That is a bullish-to-neutral conviction view, not a fear trade.

Why sell puts instead of just buying stock? Because biotech IV (implied volatility — the options market's pricing of uncertainty) is rich. RVMD carries elevated IV from a stack of upcoming binary catalysts: the daraxonrasib NDA filing, Q2 earnings on August 12, and multiple pipeline readouts on the horizon. By selling puts, this desk collects that rich IV premium now rather than waiting to see how each catalyst resolves. If the stock stays above $170, the $3.1M is pure profit.

What is the real risk? If RVMD gaps down on a pipeline setback — a regulatory reject, a safety signal, a disappointing NDA review — the seller could face significant losses below $159.70 with no floor beneath (theoretically down to zero). Biotech is binary. A bad headline could punch through the $170 strike fast. That is the honest trade-off: collect rich IV today; accept unlimited downside below ≈$160.

The $170 strike: why there? At ≈6% below spot ($181.09), $170 is a deliberate distance — far enough that normal post-ASCO consolidation or a mild pullback does not assign the stock, but close enough to collect a meaningful $10.30 ($3.1M on 3,000 contracts). It is a statement that the seller believes the post-readout floor is solid enough to sit 6% below and get paid for the risk.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

RVMD has had a remarkable 2026, driven almost entirely by clinical data. The stock was range-bound in the $120–$140 zone through early spring, then the RASolute 302 ASCO Plenary data on May 31 — OS nearly doubled, HR 0.40 — launched it into a sustained re-rating toward the $180 level. The stock is pressing its 52-week high of $184.39 and trading near all-time highs.

Key observations from the chart:

• 🚀 Post-ASCO ramp: A sharp, high-volume move from ≈$130 through $180 following the Phase 3 win
• 📈 New technical base: The $170–$175 zone has become the first meaningful support since the re-rating began — exactly where today's put seller chose to establish their strike
• ⚠️ Pre-revenue, high-multiple: With no commercial product yet, RVMD's ≈$37.6B cap rests entirely on pipeline optionality; technical levels here are guideposts, not hard floors

Gamma-Based Support & Resistance

RVMD's gamma picture is thin — this is a clinical-stage biotech with a relatively narrow options open interest base, so the formal gamma support/resistance levels are not as dense as you'd see in a large-cap name. The GEX data does, however, point to a few notable clusters:

🟠 Resistance Levels (Call Gamma Above Price):

• $180 — The strongest single call-gamma level on the board (1.62 total GEX). This is immediately above the current price of $181.09 and acts as the first meaningful ceiling; dealers hedging this level will sell into rallies past $180
• $190 — Secondary call gamma (0.11 GEX); a cleaner break of $180 opens a path to this next cluster
• $200 — Thin but present call gamma (0.18 GEX); the next upside target if momentum carries

🔵 Support Levels (Put Gamma Below Price):

• $175 — Closest put-side anchor (0.36 GEX); near-term floor
• $165 — Stronger call gamma cluster also provides support (0.74 GEX); this is the "mid" support zone
• $155 — Deepening support (0.57 GEX); well below the put-sell strike

What this means for today's trade: The put seller chose $170, sitting between the $165 and $175 gamma clusters. There is no massive gamma wall here — RVMD's gamma profile is thin throughout, which is normal for a pre-commercial biotech. The conviction comes from the fundamental/clinical story, not gamma pinning. Treat the $175 zone as the near-term floor to watch; a break of $165 would be the first meaningful technical signal that the post-ASCO narrative is fraying.

Implied Move Analysis

The options market is pricing substantial uncertainty into RVMD — as expected for a pre-revenue biotech with a stack of binary catalysts ahead:

The Aug 21 implied move is interpolated from the OPEX labels in the data; upper $210.45 / lower $142.89.

What this tells us: The market is pricing a ±$21 move by July OPEX and the lower end of the August OPEX range at $142.89 — well through today's $170 put strike. The $3.1M premium collection makes sense here: the seller is harvesting the rich IV that reflects those wide ranges. If RVMD consolidates within its current range (say, $165–$195) through August 21, the put expires worthless and the $3.1M is kept in full.

The $170 put strike sits above the $142.89 lower implied-move bound — meaning the market does assign some probability of RVMD trading below $170 by August expiry. The put seller is taking the other side of that probability and collecting $3.1M to do it.

---

🎪 Catalysts

✅ Recent Catalysts (Already Happened — the Foundation for This Trade)

• RASolute 302 Phase 3 Full Data, ASCO Plenary — May 31, 2026: daraxonrasib delivered OS 13.2 vs 6.7 months (HR 0.40, p<0.0001) in 2nd-line metastatic pancreatic cancer — a 60% reduction in the risk of death, published simultaneously in NEJM. PFS also nearly doubled (7.2 vs 3.6 months, HR 0.49). Dana-Farber called it a "transformative moment". This is the data that re-rated RVMD from ≈$130 to the $180 range.

• FDA Breakthrough Therapy Designation for daraxonrasib in previously treated metastatic PDAC with KRAS G12 mutations — a formal recognition of the clinical need and data quality (Revolution Medicines).

• Royalty Pharma $1.0B Milestone Triggered: The RASolute 302 positive readout satisfied a key milestone condition in the Royalty Pharma financing struck in June 2025 — unlocking up to $1.0B in additional non-dilutive funding on top of the $250M upfront. This materially extends the cash runway toward commercial launch without equity dilution.

• Post-ASCO analyst price-target raises — H.C. Wainwright to $195, Oppenheimer to $195, BofA to $185, Piper Sandler to $172; consensus Strong Buy with average PT ≈$186.

• FDA Expanded Access Program launched for daraxonrasib in pretreated PDAC — patients can now access the drug before NDA approval (OncLive).

🔥 Upcoming Catalysts (What Keeps IV Elevated — and Why This Trade Has Risk)

• Daraxonrasib NDA Filing (FDA Commissioner's National Priority Voucher path): This is the single biggest forward catalyst. RVMD disclosed intent in April 2026 (SEC 8-K) to submit the NDA under a novel accelerated-review pilot — no PDUFA date yet. Filing acceptance and any priority timeline announcement would de-risk the path to first revenue. No firm date; near-term.

• Q2 2026 Earnings — August 12, 2026 (after close): This falls before the August 21 expiry of today's short put. Watch for explicit NDA filing timing, updated cash runway commentary post-Royalty-Pharma milestone, and any pipeline updates. An in-line or positive earnings release is supportive; any negative surprise here would stress the $170 strike with 9 days to go.

• RASolute 301 (Phase 3, 2L NSCLC): Company expects to substantially complete enrollment in 2026. A readout — likely 2027 — opens a second multi-billion-dollar indication. Enrollment completion news this year would be a positive signal.

• RASolute 309 (RAS(ON) doublet — zoldonrasib + daraxonrasib) Registrational Trial Start: 2H 2026 — the first registrational test of the RAS(ON) combination approach. Initiation signals pipeline execution and opens a potential best-in-class path.

• 1L NSCLC Advancement Plans: company expects to disclose in 2026 — expanding the daraxonrasib program beyond 2nd-line is the next big step; any announcement extends the addressable market story.

• ESMO 2026 (October): A potential data venue for the broader RAS(ON) pipeline — not yet confirmed for this cycle but historically a venue for RVMD pipeline updates.

---

🎲 Price Targets & Scenarios Through August 21, 2026

Using both the gamma map and the implied-move ranges, here is how the three scenarios play out for RVMD and for today's short-put position:

📈 Bull Case (30% probability)

RVMD target: $195–$210

RVMD breaks above the $180 call-gamma ceiling on an NDA filing announcement or additional catalyst, tracks toward the upper implied-move bound of $210.45 by August OPEX. The August 21 $170 put expires worthless — the seller keeps the full $3.1M credit. Even a modest drift to $185–$190 accomplishes the same: any price above $170 at expiry = maximum profit for the put seller.

🎯 Base Case (50% probability)

RVMD target: $165–$185 (range-bound post-data consolidation)

Post-ASCO euphoria fades, stock digests the 5x run and consolidates between $165 and $185 — the normal behavior for a biotech after a major catalyst. The $170 put remains OTM at expiry, the seller collects the full $3.1M. This is the put seller's expected scenario: not a new rally, just RVMD holding its post-readout range while catalyst IV decays.

The ≈$170 put strike is the line in the sand: As long as RVMD closes above $170 on August 21, the position is at maximum profit. The effective ownership level only kicks in at $159.70 (strike minus premium collected).

📉 Bear Case (20% probability)

RVMD target: below $165 → potential assignment at $170

A negative headline — NDA filing delay, safety signal in an ongoing trial, sector-wide biotech risk-off, or weak Q2 earnings on August 12 — could push RVMD below $170. Below that level the put seller begins to lose money; below $159.70 the losses exceed the premium collected. This is the biotech binary: no floor exists in a clinical setback scenario, and RVMD was trading at $34 in 2025 before the data wins. The lower implied-move bound by August OPEX is $142.89 — the options market does price this tail.

Put P&L at August 21 expiry:

• RVMD at $175 (5% below today): Put worthless → +$3.1M (full credit kept) ✅
• RVMD at $170 (at-the-money): Put essentially expires at zero → ≈+$3.1M ✅
• RVMD at $160 (assigned near cost basis): Put worth $10 → breakeven ≈ flat
• RVMD at $140 (pipeline shock): Put worth $30 → loss ≈ $5.9M (−$20 × 3,000 contracts) ❗

---

💡 Trading Ideas — Four Reader Types

🛡️ Conservative (Premium Collector / "Get Paid to Wait")

Idea: Mirror the institutional logic at a smaller scale — sell a single August 21 $170 put on RVMD and collect the premium, but only if you are genuinely comfortable owning 100 shares of RVMD at ≈$160 effective cost (cash-secured).

Why this works: You collect rich biotech IV, you are fundamentally aligned with the ASCO story, and you have a 6% cushion before the strike is tested. If RVMD stays above $170, you pocket the premium. If it falls below, you effectively buy the stock at a discount to today's price.

Who this is NOT for: Anyone who cannot absorb owning RVMD at $170 or lower, or who cannot stomach the binary downside of a clinical-stage biotech. This is not a low-risk trade — it is a high-IV-premium trade with a defined cost basis.

Expected premium: ≈$10.30 per contract (≈$1,030 for one contract / 100 shares). Required cash to secure: $17,000 per contract.

⚖️ Balanced (Swing Trader / "Defined Risk, Same Direction")

Idea: Buy the August 21 $175/$165 bull put spread — sell the $175 put, buy the $165 put. Net credit of ≈$4–5 per spread; maximum risk is ≈$5–6 per spread if RVMD closes below $165. You participate in the same bullish view with a hard floor on losses.

Why this works: You're not naked on the downside. The $165 put you buy caps your loss even in a clinical-setback scenario. You sacrifice some premium vs. the naked short put, but you sleep better knowing your maximum loss is defined.

Key date to watch: August 12 earnings. A positive update before August 21 expiry helps; a negative surprise with 9 days to go is the main risk.

🚀 Aggressive (YOLO / "Play the NDA Catalyst")

Idea: Buy out-of-the-money calls — the August 21 $195 calls or the September 18 $200 calls — betting that an NDA filing announcement or additional pipeline news sends RVMD through the $190 resistance toward $200+ before expiry.

Why this could work: The upper implied-move bound by August OPEX is $210.45; by September OPEX it is $221.78. A single headline — NDA filed, priority review granted, enrollment completed in RASolute 301 — could gap the stock 10–15% overnight.

Why this could blow up: RVMD has no firm NDA filing date. The stock is already near consensus PT of ≈$186. You are buying expensive IV in a stock where the biggest single catalyst (RASolute 302) is already behind the stock. Time decay works against you every day.

Cost: ≈$5–10 per contract depending on strike and timing. Maximum loss = 100% of premium paid.

🌱 Entry-Level (Getting Started / "What Does This Trade Mean for Me?")

Real talk for beginners: When you see a "SELL PUT" trade for $3.1M, the person on the other side of this trade is not afraid — they are optimistic. They collected $3.1M in premium and are saying "I believe RVMD stays above $170 until August." If they are right, they keep all $3.1M. If they are wrong, they end up owning the stock (which they probably want anyway at that price).

What to watch: Check back on August 12 (Q2 earnings) and look for NDA filing news. If RVMD stays above $170 and those catalysts are positive, this trade wins. If a negative headline hits, watch the $170 level — a break below it means the put seller is starting to feel pressure.

For now: If you are bullish on RVMD, simply watching the stock and waiting for an entry near $170–$175 on any pullback is a reasonable retail approach. You get a similar effective cost basis to the put seller without the complexity of options mechanics.

---

⚠️ Risk Factors

Do not let the $3.1M premium collection distract from the genuine risks here:

• 🎢 Biotech is binary, full stop. RVMD was trading at $34 in early 2025. The stock has multiplied ≈5x on clinical data wins. It can and will move sharply on clinical or regulatory headlines — in either direction. A safety signal, a filing rejection, or a clinical hold could gap the stock well through the $170 strike in a single session.

• ⏰ Q2 earnings on August 12 fall INSIDE the August 21 expiry window. With 9 days between earnings and expiry, a negative earnings print or disappointing NDA commentary lands directly on the short put with minimal time to recover. This is the highest-risk timing window.

• 📋 No NDA on file, no PDUFA date. The Commissioner's National Priority Voucher pathway is novel and untested. The filing timeline is company-guided, not locked in. Any delay in submission or acceptance would disappoint a market pricing in a near-term commercial pathway.

• 🏛️ Single-asset concentration. At ≈$37.6B market cap, pre-revenue, essentially all of RVMD's valuation is daraxonrasib plus optionality on zoldonrasib and elironrasib. A stumble in the lead program — particularly in the upcoming NSCLC data or in 1L PDAC expansion — carries outsized equity downside.

• 📊 Consensus PT barely above spot. The average analyst price target is ≈$186 — only $5 above today's $181 spot. Most of the re-rating from the ASCO data has already happened. The short put seller is collecting IV that reflects future catalysts, but the consensus is not pricing a lot of additional upside from here.

• 💸 Macro / biotech sector risk. Clinical-stage biotech is rate-sensitive and sentiment-driven. A sector-wide risk-off event (macro deterioration, a high-profile clinical failure elsewhere in oncology) can pull RVMD lower even with no RVMD-specific news.

• 🔍 The tape tells us size and mechanism, not intent or identity. We know this was 3,000 contracts sold on the lit market at $10.30. We do not know the seller's other positions, their hedges, or their full thesis. This analysis is grounded in what the tape shows; the "monetizing catalyst IV" interpretation is well-supported but remains inferred.

---

🎯 The Bottom Line

Real talk: Someone just collected $3.1 million for being bullish on Revolution Medicines through August 21. They are not buying protection — they are selling it, telling the market: "I will be your buyer at $170 if you need one. And I'll get paid $3.1M to make that promise."

That kind of conviction, expressed through a premium-collection trade rather than a directional buy, is a statement about the quality of the post-ASCO story. The RASolute 302 data — OS nearly doubled, HR 0.40, in a cancer that has historically defeated every targeted therapy — is genuinely category-defining. The Royalty Pharma up-to-$1.0B milestone now triggered extends the runway. The NDA path is open. The put seller is betting the floor holds.

If you own RVMD:

• ✅ This trade is confirming your thesis — a sophisticated desk put $3.1M behind "RVMD stays above $170" through August
• 📅 Mark August 12 on your calendar for Q2 earnings — that is the next definitive catalyst before the put expires
• 🎯 Watch for NDA filing news at any time; that is the single biggest remaining catalyst and will likely move the stock 10%+ on the day
• ⚠️ If RVMD breaks below $170 on negative news, the short-put support is not infinite — reassess your own position

If you are watching from the sidelines:

• 🔵 A pullback toward $170–$175 would represent an entry at the put seller's chosen cost level — roughly where the market's implied floor sits
• 📊 Wait for either an NDA filing announcement or Q2 earnings for a cleaner entry signal
• ⏰ The August OPEX window (ending August 21) is the tactical horizon to watch

If you are cautious on biotech:

• The $142.89 lower implied-move bound by August OPEX is a reasonable stress scenario — do not size into RVMD as if the downside is capped
• The binary nature of pre-revenue oncology means any of the upcoming catalysts can move this stock 20%+ in either direction

Mark your calendar — Key dates:

• 📅 June 26, ≈06:30 ET — ✅ RESOLVED: OPRA OI rose 0 → 3,001 (Δ +3,001), confirming the fresh short-put open (STO)
• 📅 August 12, 2026 — Q2 2026 earnings (after close) — inside the August 21 put expiry window
• 📅 August 21, 2026 — Option expiry for today's short put
• 📅 Anytime / near-term — daraxonrasib NDA filing announcement under Commissioner's National Priority Voucher pathway
• 📅 2H 2026 — RASolute 309 (RAS(ON) doublet) registrational trial initiation
• 📅 2026 (timing TBD) — RASolute 301 enrollment completion + 1L NSCLC advancement plan disclosure
• 📅 October 2026 — ESMO 2026 (potential data update venue)

The lesson here: A $3.1M premium sale is not a loud trade. It does not sweep the tape or print like a panic buy. But it is a sophisticated statement of conviction — a desk putting nearly $17M of buying power at risk (300,000 shares × $170 strike notional if fully assigned) to collect $3.1M, because they believe the biggest Phase 3 win in pancreatic cancer in decades has built a durable floor. Pay attention to quiet, structured money. It often knows something about probabilities that the headline flow does not.

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. Selling uncovered or cash-secured put options carries the risk of being obligated to purchase the underlying stock at the strike price regardless of the current market value, which may represent a significant loss. This analysis is for educational and informational purposes only and does not constitute financial advice, a solicitation, or a recommendation to buy or sell any security. Past performance, including historical options flow, does not guarantee future results. RVMD is a pre-revenue clinical-stage biotechnology company; its stock is subject to extreme volatility around clinical trial results, regulatory decisions, and other binary events. Always conduct your own research and consult a qualified financial professional before making any investment decisions. Net premium collected: $3.1M (credit).

---

About Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies that block RAS proteins in their active (ON) state across multiple tumor types including pancreatic and lung cancer. Lead asset daraxonrasib (RMC-6236) recently posted a practice-changing Phase 3 win in 2nd-line metastatic pancreatic cancer with OS nearly doubled versus chemotherapy. Market cap ≈$37.6B. Sector: Biotechnology.

---

Last updated: June 26, 2026 — morning OI check confirmed the August $170 put as a fresh short OPEN (STO): OI 0 → 3,001 (Δ +3,001). Size-proven open verdict holds.